Abstract 2123P
Background
Immuno-nutritional scores like neutrophil-lymphocyte ratio (NLR), prognostic nutritional index (PNI), modified Glasgow prognostic score (mGPS) and controlling nutritional status (CONUT) have been developed to reflect the chronic inflammatory state and malnutrition induced by cancer, and to predict clinical outcomes. This study aims to investigate the prognostic value of these scores in hospitalized patients with lung cancer as we know that unscheduled admission in patients with cancer may imply organ fragility.
Methods
In this retrospective study, we examined patients with lung cancer and unscheduled hospitalizations that took place between June 2021 and May 2022 within the Medical Oncology Service of La Paz University Hospital in Madrid, Spain.
The optimal cutoff for continuous variables was evaluated with Youden index. Survival since admission was estimated with the Kaplan-Meier method. Univariate and multivariate analyses were performed by Cox regression model to determine independent prognostic factors. Areas under the curve (AUCs) or ROCs were calculated to evaluate the discriminatory ability.
Results
We admitted 158 patients with a median age of 68 years, majority of male (66.5%) and stage IV predominance (84.8%). The median follow-up was 14.9 months. The median overall survival since admission was 3.3 months (95%CI: 1.86-7.74). The optimal cut-off value for NLR was calculated to be 6 (Youden index=0.2) and for PNI was 40 (Youden index=0.1). In univariate analysis, poorer survival was associated with NLR>6 (1.87 vs 7.40 months, p=0.006, HR 1.67, 95%CI 1.16-2.42) and PNI<40 (1.67 vs 4.97 months, p=0.044, HR 1.49, 95%CI 1.01-2.20) and was not associated with CONUT (p=0.70) or mGPS (p=0.067). In the multivariate analysis only NLR>6 was an independent prognostic factor (p=0.042, HR 1.61, 95%CI 1.02-2.57). The ROC curve to evaluate the discriminatory ability of 30-day mortality was only significant in the case of NLR>6 (p=0.035, AUC 0.599, 95%CI 0.51-0.69).
Conclusions
In our setting, NLR was the most robust score for estimating prognosis in hospitalized patients with lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2065P - Communication on the first medical oncology appointment: What do cancer patients want?
Presenter: Rodrigo Vicente
Session: Poster session 06
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06